Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

953
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
953
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.3K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026
Same author

Early α-synuclein-mediated mitochondrial dysfunction in a human cell model of Parkinson's disease dementia.

Communications biology·2026
Same author

rAAV Fbxo7 gene therapy rescues the progressive nigrostriatal pathology in a mouse model of juvenile parkinsonism.

Acta neuropathologica communications·2026
Same author

Stem cell treatments and Parkinson's disease: Science and misconceptions.

Journal of Parkinson's disease·2026
Same author

The challenges of choosing your pluripotent stem cell line.

Stem cell reports·2026

Related Experiment Video

Updated: Jan 10, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

606

Clinical trial highlights: Dopamine cell-replacement therapies.

Saeed Kayhanian1,2,3, Roger A Barker1,3,4

  • 1Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

Journal of Parkinson'S Disease
|November 25, 2025
PubMed
Summary

Stem cell therapy offers new hope for Parkinson's disease by replacing lost dopamine neurons. Derived from pluripotent stem cells, these cells show promise in ongoing clinical trials, overcoming limitations of fetal tissue sources.

Keywords:
Cell therapyParkinson's diseaseclinical trialsneurosurgerystem cell

More Related Videos

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

7.6K
Directed Dopaminergic Neuron Differentiation from Human Pluripotent Stem Cells
06:40

Directed Dopaminergic Neuron Differentiation from Human Pluripotent Stem Cells

Published on: September 15, 2014

17.1K

Related Experiment Videos

Last Updated: Jan 10, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

606
Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
12:13

Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Published on: July 11, 2019

7.6K
Directed Dopaminergic Neuron Differentiation from Human Pluripotent Stem Cells
06:40

Directed Dopaminergic Neuron Differentiation from Human Pluripotent Stem Cells

Published on: September 15, 2014

17.1K

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Stem Cell Biology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder primarily affecting motor function due to dopaminergic neuron loss.
  • Cell grafting has been explored since the 1980s for PD, but outcomes are inconsistent.
  • Previous cell sources from fetal brain tissue present significant challenges and variability.

Purpose of the Study:

  • To investigate the potential of human pluripotent stem cells as a source for dopamine neuron replacement in Parkinson's disease therapy.
  • To address the limitations associated with traditional cell sources for PD treatments.

Main Methods:

  • Generation of authentic midbrain dopamine cells from human pluripotent stem cells.
  • Initiation of first-in-human clinical trials to evaluate the safety and efficacy of this approach.

Main Results:

  • Successful derivation of authentic midbrain dopamine cells from human pluripotent stem cells is now achievable.
  • First-in-human clinical trials utilizing these stem cell-derived dopamine neurons are currently in progress.

Conclusions:

  • Human pluripotent stem cells represent a viable and promising cell source for Parkinson's disease regenerative therapy.
  • Ongoing clinical trials are crucial for validating the therapeutic potential of this advanced cell-based approach for PD.